NCT04470830View on ClinicalTrials.gov

A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

CompletedOBSERVATIONAL
Enrollment

718

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions
Essential Hypertension
Trial Locations (1)

42415

Yeungnam University Medical Center, Daegu

All Listed Sponsors
lead

Celltrion Pharm, Inc.

INDUSTRY

NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea | Biotech Hunter | Biotech Hunter